Mary Adams

1.3k citations

26 papers · 1.1k indexed · h-index 14

Physiology top 5%
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 3
Hematology top 5%
- Multiple Myeloma Research and Treatments 10
Organic Chemistry top 5%
- Quinazolinone synthesis and applications 3
Oncology top 10%
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 5
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 4
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 3
Molecular Biology
- Protein Degradation and Inhibitors 3

Co-authors: J. Blake Bartlett Peter SchäferLei WuDavid Stirling George W. Muller Troy Carter Roger Chen Peter J. Connolly
Cited by: Physiology Genetics Hematology
Journals: Journal of Clinical Oncology (3 papers)Blood (3 papers)Cancer Research (1 paper)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Mary Adams

24 papers receiving 1.1k citations

Peers

Countries citing papers authored by Mary Adams

Since Specialization

Citations

This map shows the geographic impact of Mary Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Adams more than expected).

Fields of papers citing papers by Mary Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Adams. The network helps show where Mary Adams may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mary Adams, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary Adams Line = papers co-authored together Mary Adams links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo The Prostate ·Jake Y. Henry,Ling Lu,Mary Adams,B Meyer,J. Blake Bartlett,Angus Dalgleish,Christine Galustian	2011	18
2	Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers Cancer Immunology Immunotherapy ·Lei Wu,Anastasia Parton,Ling Lu,Mary Adams,Peter Schäfer,J. Blake Bartlett	2010	48
3	Abstract 5386: Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo Cancer Research ·Jake Y. Henry,Ling Lü,Mary Adams,B Meyer,Blake Bartlett,Angus Dalgleish,Christine Galustian	2010	2
4	Abstract A43: Lenalidomide enhances the anti-proliferative activity of docetaxel in in vivo and in vitro models of prostate cancer Clinical Cancer Research ·Jake Y. Henry,Ling Lü,Mary Adams,B Meyer,Blake Bartlett,Angus Dalgleish	2010	0
5	Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Ronghui Lin,Sigmond G. Johnson,Peter J. Connolly,Steven K. Wetter,Eva Binnun,Terry V. Hughes,William V. Murray,Niranjan B. Pandey,Sandra Moreno-Mazza,Mary Adams,Angel R. Fuentes‐Pesquera,Steven A. Middleton	2009	112
6	Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes. Blood ·Linghua Zhang,Mary Adams,Jolanta Kosek,Peter Schäfer,J. Blake Bartlett	2009	2
7	Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,Lily L. Searle,Terry V. Hughes,Amanda K. Beck,Peter J. Connolly,M.C. Abad,Michael P. Neeper,Geoffrey T. Struble,Barry A. Springer,Stuart L. Emanuel,Robert H. Gruninger,Niranjan B. Pandey,Mary Adams,Sandra Moreno-Mazza,Angel R. Fuentes‐Pesquera,Steven A. Middleton,Lee M. Greenberger	2008	48
8	A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity Bioorganic & Medicinal Chemistry Letters ·Terry V. Hughes,Guozhang Xu,Steven K. Wetter,Peter J. Connolly,Stuart L. Emanuel,Prabha Karnachi,Scott R. Pollack,Niranjan B. Pandey,Mary Adams,Sandra Moreno-Mazza,Steven A. Middleton,Lee M. Greenberger	2008	24
9	4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu,M.C. Abad,Peter J. Connolly,Michael P. Neeper,Geoffrey T. Struble,Barry A. Springer,Stuart L. Emanuel,Niranjan B. Pandey,Robert H. Gruninger,Mary Adams,Sandra Moreno-Mazza,Angel R. Fuentes‐Pesquera,Steven A. Middleton	2008	80
10	Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1) Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang,Ronghua Li,Peter J. Connolly,Stuart L. Emanuel,Angel R. Fuentes‐Pesquera,Mary Adams,Robert H. Gruninger,Jabed Seraj,Steven A. Middleton,Jeremy Davis,David Moffat	2007	11
11	Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors Molecular Pharmacology ·Stuart L. Emanuel,Terry V. Hughes,Mary Adams,Catherine A. Rugg,Angel R. Fuentes‐Pesquera,Peter J. Connolly,Niranjan B. Pandey,Sandra Moreno-Mazza,Jeannene Butler,Virna Borowski,Steven A. Middleton,Robert H. Gruninger,Jennifer R. Story,Cheryl Napier,Beth Hollister,Lee M. Greenberger	2007	30
12	Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab Journal of Clinical Oncology ·J. Blake Bartlett,Liangxing Wu,Mary Adams,Peter Schäfer,George W. Muller,David Stirling	2007	12
13	Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors Bioorganic & Medicinal Chemistry Letters ·Ronghui Lin,George Chiu,Yang Yu,Peter J. Connolly,Shengjian Li,Yanhua Lü,Mary Adams,Angel R. Fuentes‐Pesquera,Stuart L. Emanuel,Lee M. Greenberger	2007	111
14	Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents Bioorganic & Medicinal Chemistry Letters ·Ronghui Lin,Peter J. Connolly,Yanhua Lü,George Chiu,Shengjian Li,Yang Yu,Shenlin Huang,Xun Li,Stuart L. Emanuel,Steven A. Middleton,Robert H. Gruninger,Mary Adams,Angel R. Fuentes‐Pesquera,Lee M. Greenberger	2007	75
15	Quantitative Determination of ZnO Nano-Particles in Human Bronchoalveolar Carcinoma-Derived Lung Cancer Cells Mary Adams,Weisheng Lin,Yinfa Ma	2007	0
16	A Novel Bioluminescent Tumor Model of Human Renal Cancer Cell Lines: An In Vitro and In Vivo Characterization The Journal of Urology ·Christoph Peter,Jan T. Kielstein,Regina H. Clarke‐Katzenberg,Mary Adams,Maria Pitsiouni,Neeraja Kambham,Mobin Karimi,Ken M. Kengatharan,John P. Cooke	2007	8
17	3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation Bioorganic & Medicinal Chemistry Letters ·Ronghui Lin,Yanhua Lü,Steven K. Wetter,Peter J. Connolly,Ignatius J. Turchi,William V. Murray,Stuart L. Emanuel,Robert H. Gruninger,Angel R. Fuentes‐Pesquera,Mary Adams,Niranjan B. Pandey,Sandra Moreno-Mazza,Steven A. Middleton,Linda K. Jolliffe	2005	21
18	Detection of thromboxane A2 receptor mRNA in rabbit nodose ganglion neurons Neuroscience Letters ·Michael Wacker,John B. Tyburski,Chad P. Ammar,Mary Adams,James A. Orr	2005	13
19	2‐Chloro N⁶‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate is a selective high affinity P2Y₁ receptor antagonist British Journal of Pharmacology ·José L. Boyer,Mary Adams,R. Gnana Ravi,Kenneth A. Jacobson,T. Kendall Harden	2002	78
20	In vivo induction of HPV 16 specific cytotoxic ctl and T-helper immunity in patients with advanced cervical cancer using autologous dendritic cells (dc) pulsed with tumour lysate as a potential anti-cancer vaccine European Journal of Cancer ·Mary Adams,Annemieke de Jong,H. Navabi,C. Lippetz,Bharat Jasani,Stephen Man,Alison Fiander,Ronald Wood,Sabine Berg,Malcolm D. Mason	2001	3

About Mary Adams

Mary Adams is a scholar working on Hematology, Oncology and Physiology, having authored 26 papers that have together received 1.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (10 papers), HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Advanced Breast Cancer Therapies (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Quinazolinone synthesis and applications (3 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Physiology (84 citations), Genetics (175 citations) and Hematology (180 citations). Mary Adams has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include J. Blake Bartlett, Peter Schäfer, Lei Wu, David Stirling, George W. Muller, Troy Carter, Roger Chen, Peter J. Connolly, Angel R. Fuentes‐Pesquera and Stuart L. Emanuel. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact